We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Duke University Selects Illumina's Infinium HumanHap550 BeadChip

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Duke University Selects Illumina's Infinium HumanHap550 BeadChip"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Illumina, Inc. has announced that Duke University's Center for Human Genetics (CHG) has selected the Infinium HumanHap550 BeadChip for an Autism study of over 1,800 individuals and their families.

The identification of the genes which contribute to complex disease like autism will lead to the development of enhanced diagnostic tools, early detection, and improved health outcomes for patients and their families.

Drs. Margaret Pericak-Vance and John R. Gilbert will lead the Duke CHG team of autism researchers.

According to Dr. Pericak-Vance, "Multiple genes and the interactions of these genes contribute to diseases like autism, making their identification very difficult."

"New technologies and creative thinking are required for the advancement of these projects."

"We are delighted to be working in concert with Illumina and we are excited about the speed, throughput and data completeness we are experiencing with this product."

Dr. Gilbert added, "We are excited to have the opportunity to use Illumina's state of the art, whole-genome genotyping system to accelerate the search for autism risk genes."